Unfit sufferers also have the choice of venetoclax plus obinutuzumab (VO) as frontline therapy. This is based on the phase III demo that compared VO with ClbO in elderly/unfit patients.113 VO was exceptional regarding response amount and development-cost-free survival, and had a similar protection profile. With this demo VO was https://guyv480jqt0.birderswiki.com/user